4Front Ventures (FFNT) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $17.1 million, with adjusted EBITDA of $1.0 million, reflecting disciplined growth and operational efficiency.

• Matteson facility in Illinois is operational and nearing full capacity, supporting long-term expansion and increased market share in a supply-constrained environment.

• Massachusetts wholesale revenue grew over 56% quarter-over-quarter, with October marking a record month and 91% year-over-year growth.

• Washington operations delivered record sales, with a 6.6% quarter-over-quarter revenue increase, top-three market share in edibles and vapes, and 473,000 units sold in Q3.

• Leadership team with deep industry and financial expertise, driving operational efficiency and market share gains.

Financial highlights

• Q3 2024 total revenue was $17.1 million, down from $18.7 million in Q2 2024; pro forma revenue including Washington was $26.9 million.

• Adjusted EBITDA for Q3 was $1.0 million, down from $2.6 million in Q2, mainly due to retail softness and increased costs at Matteson.

• Net loss for Q3 2024 was $6.4 million, compared to a net loss of $62.1 million in Q3 2023.

• Ended Q3 with $1.2 million in cash and $68.9 million in total debt.

• Gross profit for Q3 2024 was $3.7 million, with a gross margin of 21.4%.

Outlook and guidance

• Scaling Matteson facility to 34,800 sq ft of canopy by mid-January 2025, targeting over 3,000 pounds of biomass and 2,000 pounds of sellable flower monthly, with most output pre-sold.

• Management expects improved gross margin and a return to growth as wholesale ramps up and Matteson reaches full capacity.

• Anticipates monthly wholesale revenue of approximately $1 million in Massachusetts in the near term.

• New product launches planned for Q4 and Q1, including Mission strains, Marmas edibles, Crystal Clear vapes, and 'Smoke Breaks.'

• Confident in achieving sustainable positive cash flows from operations in Q4 2024.